Tag Archives: Depression

New Ketamine Data

As was discussed at length in December’s NeuroPerspective, the quest for a rapid-acting anti-depressant (RAAD) continues to be one of the most closely watched races in neuropharmacology. A small but intriguing Mt-Sinai sponsored study comparing ketamine with the anesthetic midazolam … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment

Weather Update

The National Weather Service reports that there are some breaks in the thick layer of clouds and fog which has covered the CNS space for much of the past year. While there are not yet clear signs of a summer … Continue reading

Posted in Big Pharma, Biotech, Science | Tagged , , , , | Leave a comment

Of Persistence and Ethics in Phase III

Persistence paid off for Lundbeck and Takeda, whose first Phase III program for their antidepressant Lu AA21004 failed. With revised dosing, they ran another extensive set of pivotal trials, have announced that they will be filing for regulatory approval in … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , , , , , | 1 Comment

Depression Trial Contrarians

The latest issue of Neuropsychopharmacology has a provocative article by Undurraga and Balderassini regarding a meta-analysis they conducted of some thirty years of depression trials, an area that has grown increasingly and expensively frustrating as trials have been commonly compromised … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment